Pharmacosmos has a strong track record for identification of
promising pharmaceutical compounds for iron infusion therapy.
Pharmacosmos has a unique in-house expertise in manufacturing
process development according to current Good Manufacturing
Practice (GMP) of active pharmaceutical ingredients (API).
Pharmacosmos establishes partnerships and strategic alliances
with leading pharmaceutical companies whenever this may advance the
development of Pharmacosmos' pharmaceutical compounds.
Pharmacosmos may choose to out-license clinical development of
potential pharmaceutical compounds.
Learn more about our treatments
for iron deficiency anaemia and high quality clinical
grade dextran biopolymers.